NEUROONE MED.TECH.DL-,001

NeuroOne Medical Technologies filed a prospectus supplement for an at-the-market offering to sell common stock of up to $13.4 million. The program runs under the existing capital-on-demand agreement with JonesTrading and allows sales at prevailing market prices; the filing was made with the SEC. The stock trades at $3.24, near its 52-week low, and is down about 29% year-to-date, while analysts warn of rapid cash burn. Separately, the company reported Q2 results with EPS of -$0.25 and revenue of $2.4 million, missing expectations, yet the stock rose despite the numbers. » Plus sur de.investing.com

NeuroOne Medical Technologies released figures for the quarter ended March 31, 2026: loss per share was $0.25 (prior year: -$0.420). Revenue rose 71.94% to $2.4 million from $1.4 million in the year-ago quarter. The results were announced on May 12, 2026. » Plus sur finanzen.net

NeuroOne reported Q2 FY2026 EPS of -$0.25 (expectation -$0.2202) and revenue of $2.4m (expectation $2.58m), missing both forecasts. Revenue rose 72% year‑over‑year, but gross margin fell and cash reserves have declined markedly over the past six months. The stock fell 0.46% in premarket trading and management, despite missing targets, emphasizes a strategic focus on FDA approvals and planned international certifications. Risks remain including margin pressure, constrained liquidity and possible delays in international expansion. » Plus sur de.investing.com